Walk into enough gas stations, smoke shops or convenience stores in America and eventually you will encounter a strange modern pharmacy hiding in plain sight. Brightly colored “energy shots.” “Herbal” sexual enhancement pills. Kratom capsules and concentrated extracts. Mood boosters. “Focus” supplements. Products with names that sound more like energy drinks, nightclub promotions or internet memes than substances capable of affecting the human brain and body.
Many consumers assume these products are either harmless novelties or weak alternatives to prescription drugs. Increasingly, that assumption may be dangerously wrong.
A recent segment on HBO’s Last Week Tonight with John Oliver highlighted the rapidly expanding and often poorly understood world of so-called “gas station drugs,” focusing on sexual enhancement supplements, kratom products, concentrated 7-OH compounds and tianeptine, a substance sometimes referred to by critics as “gas station heroin.”
While the segment used comedy to expose the absurdity of some of these products and marketing practices, the underlying regulatory and public-health concerns are very real.
And from a regulatory perspective, the issue is much larger than many consumers realize.
A Regulatory Gap Decades in the Making
Much of the current situation traces back to the Dietary Supplement Health and Education Act of 1994 (DSHEA), which dramatically changed how dietary supplements are regulated in the United States.
Unlike prescription drugs, dietary supplements generally do not require FDA premarket approval before being sold to consumers.
In practice, that means many supplement manufacturers are largely responsible for determining the safety of their own products before they enter the market.
FDA can act against unsafe or adulterated products, but often only after injuries occur, adverse events are reported, products are found to contain undeclared ingredients, or broader public-health concerns emerge.
That creates a fundamentally reactive system. And in rapidly evolving markets involving online suppliers, imported ingredients and constantly changing formulations, regulators are often forced into a perpetual game of catch-up.
Warning Letter Cites Serious Deficiencies at Pharma Facility
Serious Sterility and CGMP Deficiencies at ProRx Outsourcing Facility The FDA has issued a significant Warning Letter to ProRx LLC, an FDA-registered outsourcing facility located in Exton, Pennsylvania, citing major violations involving sterile drug compounding...
FDA-Approved Vivistim: A New Pathway in Stroke Recovery
Vivistim implantable vagus nerve stimulator. Source: Vivistim.com.FDA-Approved Vagus Nerve Stimulation Device Opens a New Pathway in Stroke Recovery A company behind one of the world’s most closely watched neurorehabilitation technologies is preparing for a major new...
FDA Cites Data Integrity and OOS Failures at Intas Pharma
FDA Warning Letter: Data Integrity and OOS Failures at Intas Pharmaceuticals Limited The U.S. Food and Drug Administration issued a Warning Letter to Intas Pharmaceuticals Limited citing significant violations of Current Good Manufacturing Practice (CGMP) at its...
FDA Warning Letter Cites Systemic Aseptic Manufacturing Failures
Medline Warning Letter Signals Systemic Quality Failures in Cardiovascular Device Manufacturing The FDA has issued a Warning Letter to Medline Industries (NAMIC Division) following a December 2025 inspection, identifying significant Quality System Regulation (QSR)...
FDA Approves First Gene Therapy for Genetic Hearing Loss
FDA Approves First Gene Therapy for Genetic Hearing LossRapid Review and Breakthrough Science Converge in Landmark OTOF Therapy The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first gene therapy for a form of inherited hearing loss caused by mutations in...
April 2026 Update for FDA QMSR Inspection Results
April 2026 Update for FDA QMSR Inspection ResultsConfirming the Shift to System-Level, Risk-Based Inspection When FDA’s Quality Management System Regulation (QMSR) took effect on February 2, 2026, the regulatory framework became formally aligned with ISO 13485. What...
Clinical Evidence and Regulatory Pathway
Optune Pax was approved through the Premarket Approval (PMA) pathway, the FDA’s most rigorous regulatory review process for medical devices. Approval was based on data from a randomized controlled clinical trial conducted under an Investigational Device Exemption (IDE).
In the pivotal study, the device was used in combination with standard chemotherapy agents gemcitabine and nab-paclitaxel (GnP). Patients receiving combination therapy experienced an average improvement in overall survival of approximately two months compared with chemotherapy alone.
The most common device-related adverse effects reported were localized skin reactions associated with the transducer arrays applied to the abdomen.
The device previously received Breakthrough Device designation in December 2024, allowing for expedited development and review due to its potential to address a life-threatening condition with limited treatment options.
Why This Matters
Pancreatic cancer remains one of the most challenging cancers to treat. According to the National Cancer Institute, the disease accounted for an estimated 67,440 new diagnoses and nearly 52,000 deaths in the United States in 2025, reflecting its aggressive nature and the limited effectiveness of existing therapies.
The approval of Optune Pax represents an example of device-based oncology therapies expanding beyond surgical tools and diagnostic technologies into direct therapeutic interventions.
It also highlights several broader trends in medical device regulation. Wearable and home-use therapeutic devices are becoming more prominent in FDA approvals. The Breakthrough Device designation continues to accelerate development timelines for technologies addressing life-threatening diseases. And device-drug combination treatment strategies, in this case pairing TTFields with chemotherapy, are becoming increasingly common in oncology.
MDP Perspective
The approval of Optune Pax illustrates how medical device innovation is increasingly focused on non-invasive therapies that can be integrated into patients’ daily lives. As healthcare systems shift toward decentralized care models, regulators are placing greater emphasis on technologies that support treatment outside traditional hospital settings.
For device manufacturers, this approval also underscores the importance of strong clinical evidence when pursuing the PMA pathway, particularly for novel therapeutic technologies. While the survival benefit observed in the clinical trial was modest, the device introduces a new mechanism of action that could open the door to future advances in electro-therapeutic oncology treatments.
As FDA continues to promote patient-centered device innovation, companies developing wearable therapeutic platforms and home-use treatment systems should expect increasing regulatory attention to usability, training, and post-market monitoring.
The Hidden Drug Problem
One of the most concerning issues involves sexual enhancement supplements. For years, FDA laboratory testing has repeatedly identified undeclared pharmaceutical ingredients in products marketed as “all natural” or “herbal” sexual enhancement aids.
Some products have been found to contain sildenafil (the active ingredient in Viagra), tadalafil (Cialis), dapoxetine, or other prescription drug ingredients. In some cases, the dosages were reportedly far higher than approved prescription levels.
That creates serious risks. Consumers may unknowingly combine these substances with blood pressure medications, heart medications, nitrates, alcohol, or other drugs that can interact dangerously with erectile dysfunction medications.
And because many of these products are manufactured through fragmented supply chains with little transparency, consumers often have no reliable way to know what is inside the package. Even visually identical products may contain entirely different ingredients or concentrations.
From a regulatory standpoint, these products blur the line between supplements, counterfeit pharmaceuticals, adulterated drugs, and undeclared chemical mixtures.
Kratom and the Rise of High-Potency Extracts
Another rapidly growing area of concern involves kratom and related concentrated compounds. Kratom is derived from a Southeast Asian plant whose active compounds can produce stimulant effects at lower doses and opioid-like effects at higher doses.
Supporters argue kratom may help some individuals manage pain or reduce opioid dependence. Critics point to addiction potential, withdrawal symptoms, inconsistent manufacturing, contamination concerns, and increasingly potent formulations.
Particularly concerning are newer concentrated compounds such as 7-hydroxymitragynine (7-OH), which researchers have reported may interact with opioid receptors at extremely high potency levels. Unlike traditional herbal products, many of these newer formulations are highly processed, concentrated and aggressively marketed.
Some products are sold in packaging that resembles energy shots, candy, supplements, or wellness products, despite potentially significant pharmacological effects. And because regulations vary widely from state to state, products banned in one state may continue appearing in neighboring jurisdictions or online marketplaces.
Tianeptine and “Gas Station Heroin”
Perhaps the most alarming products discussed in recent investigations involve tianeptine. Tianeptine is approved as an antidepressant in some countries but is not approved by FDA for medical use in the United States.
Nevertheless, products containing tianeptine have appeared widely in convenience stores, smoke shops, gas stations, and online retailers.
Public health officials and poison-control experts have increasingly warned about addiction, withdrawal, overdoses, and deaths associated with tianeptine products.
Some states have moved to ban or restrict the substance. But as regulators crack down on one compound, manufacturers and distributors often pivot rapidly toward new analogs, reformulations or replacement products.
That dynamic creates a regulatory whack-a-mole problem that traditional enforcement systems struggle to contain.
Why FDA Often Appears Reactive
Consumers sometimes ask “If these products are dangerous, why are they still being sold?” The answer is complicated.
FDA issues recalls, import alerts, warning letters, public safety advisories, and laboratory findings involving these products. But the agency faces enormous challenges due to limited staffing, fragmented supply chains, online sales, imported ingredients, rapidly changing formulations, and legal limitations involving supplements regulation.
In many cases, FDA must first demonstrate that a product is adulterated, misbranded, unsafe, or illegally marketed before taking significant enforcement action. Meanwhile, new products continue entering the market faster than regulators can evaluate them.
The Public Health Challenge Ahead
The growing “gas station drugs” market represents a complicated public-health issue because it sits at the intersection of addiction, chronic pain, supplement regulation, mental health, consumer demand, online commerce, and distrust of traditional healthcare systems.
Some consumers may turn to these products because they lack healthcare access, cannot afford prescriptions, are seeking alternatives to opioids, or mistakenly assume “natural” products are inherently safe. That reality makes simplistic solutions difficult.
Broad prohibition alone may simply push products underground or accelerate the emergence of new synthetic alternatives. At the same time, the current environment where products with potentially powerful pharmacological effects can sometimes be sold with inconsistent labeling, undeclared ingredients and limited oversight creates serious and growing risks for consumers.
What Consumers Should Understand
Consumers should not assume that products sold in gas stations or convenience stores are FDA-approved, clinically tested, consistently manufactured, accurately labeled, or free from pharmaceutical ingredients. And “herbal,” “natural” or “supplement” labeling does not necessarily mean a product is low risk.
As FDA and state regulators continue struggling to keep pace with this rapidly evolving market, consumers increasingly bear responsibility for understanding what they are putting into their bodies. That may be the most troubling reality of all.